• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Achieving Improved Survival Outcomes in Advanced Breast Cancer.

作者信息

Rugo Hope S

机构信息

From the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco.

出版信息

N Engl J Med. 2019 Jul 25;381(4):371-372. doi: 10.1056/NEJMe1906236.

DOI:10.1056/NEJMe1906236
PMID:31340099
Abstract
摘要

相似文献

1
Achieving Improved Survival Outcomes in Advanced Breast Cancer.改善晚期乳腺癌的生存结局
N Engl J Med. 2019 Jul 25;381(4):371-372. doi: 10.1056/NEJMe1906236.
2
Ribociclib in premenopausal women with advanced breast cancer.瑞博西尼用于绝经前晚期乳腺癌女性患者
Lancet Oncol. 2018 Jul;19(7):850-852. doi: 10.1016/S1470-2045(18)30367-X. Epub 2018 May 24.
3
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.来曲唑联合内分泌治疗激素受体阳性、晚期乳腺癌的绝经前妇女（MONALEESA-7）：一项随机 3 期临床试验。
Lancet Oncol. 2018 Jul;19(7):904-915. doi: 10.1016/S1470-2045(18)30292-4. Epub 2018 May 24.
4
Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib.晚期乳腺癌新型疗法的发现与研发：瑞博西尼的快速发展
Ann Oncol. 2017 Aug 1;28(8):2021-2024. doi: 10.1093/annonc/mdx226.
5
Ribociclib Lengthens Breast Cancer Survival.瑞博西利延长乳腺癌患者生存期。
Cancer Discov. 2016 Dec;6(12):1299. doi: 10.1158/2159-8290.CD-NB2016-138. Epub 2016 Nov 3.
6
Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.来曲唑与阿那曲唑治疗绝经后激素受体阳性、人表皮生长因子受体 2 阴性晚期乳腺癌的疗效和安全性的 Meta 分析
Expert Rev Anticancer Ther. 2018 Mar;18(3):201-213. doi: 10.1080/14737140.2018.1435275. Epub 2018 Feb 19.
7
[Ribociclib in combination with endocrine therapy improves overall survival of pre-/perimenopausal breast cancer patients].瑞博西尼联合内分泌治疗可提高绝经前/围绝经期乳腺癌患者的总生存期
Strahlenther Onkol. 2020 Mar;196(3):286-288. doi: 10.1007/s00066-019-01574-y.
8
Expanding ribociclib use.扩大瑞博西尼的使用范围。
Nat Rev Clin Oncol. 2018 Aug;15(8):470-471. doi: 10.1038/s41571-018-0051-x.
9
Ribociclib and Endocrine Therapy in Breast Cancer. Reply.瑞博西尼与乳腺癌内分泌治疗。回复
N Engl J Med. 2019 Oct 17;381(16):1592-1593. doi: 10.1056/NEJMc1911188.
10
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.MONALEESA-2 随机研究中，新诊断的 HR+、HER2-晚期乳腺癌患者中，接受来曲唑联合瑞波西利与来曲唑单药相比的疗效。
Breast Cancer Res Treat. 2018 Feb;168(1):127-134. doi: 10.1007/s10549-017-4518-8. Epub 2017 Nov 21.

引用本文的文献

1
Prognostic factors analysis and nomogram construction of breast cancer patients lung metastases and bone metastases.乳腺癌患者肺转移和骨转移的预后因素分析及列线图构建
Surg Open Sci. 2025 Apr 23;26:28-38. doi: 10.1016/j.sopen.2025.04.006. eCollection 2025 Jun.
2
Effects of using app-based interventions on quality of life among breast cancer patients: a systematic review with meta-analysis.基于应用程序的干预措施对乳腺癌患者生活质量的影响：一项荟萃分析的系统评价
Ann Med. 2025 Dec;57(1):2499027. doi: 10.1080/07853890.2025.2499027. Epub 2025 May 6.
3
Effectiveness of aerobic exercise intervention on cardiovascular disease risk in female breast cancer: a systematic review with meta-analyses.
有氧运动干预对女性乳腺癌患者心血管疾病风险的影响：一项荟萃分析的系统评价
BMC Public Health. 2024 Dec 2;24(1):3355. doi: 10.1186/s12889-024-20592-9.
4
Atrial fibrillation and breast cancer-Vicious twins? A systematic review and meta-analysis.心房颤动与乳腺癌——难兄难弟？一项系统评价与荟萃分析
Front Cardiovasc Med. 2023 Mar 10;10:1113231. doi: 10.3389/fcvm.2023.1113231. eCollection 2023.
5
Cost-Effectiveness Analysis of Abemaciclib plus Fulvestrant versus Placebo plus Fulvestrant in Patients with Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.阿贝西利联合氟维司群与安慰剂联合氟维司群用于激素受体阳性、ERBB2阴性乳腺癌患者的成本效益分析
Breast Care (Basel). 2022 Jun;17(3):237-243. doi: 10.1159/000518551. Epub 2021 Sep 9.
6
Relevance of Membrane Contact Sites in Cancer Progression.膜接触位点在癌症进展中的相关性。
Front Cell Dev Biol. 2021 Jan 12;8:622215. doi: 10.3389/fcell.2020.622215. eCollection 2020.
7
Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series.哌柏西利联合氟维司群或依维莫司联合依西美坦用于ER+/HER2-、组织学类型为小叶型的经治晚期乳腺癌患者：一项多中心回顾性患者系列的倾向评分匹配分析
J Pers Med. 2020 Dec 18;10(4):291. doi: 10.3390/jpm10040291.
8
Nano-Encapsulation of Coenzyme Q10 in Secondary and Tertiary Nano-Emulsions for Enhanced Cardioprotection and Hepatoprotection in Human Cardiomyocytes and Hepatocytes During Exposure to Anthracyclines and Trastuzumab.将辅酶 Q10 纳米包封在二级和三级纳米乳液中，以增强人心肌细胞和肝细胞在暴露于蒽环类药物和曲妥珠单抗时的心脏保护和肝脏保护。
Int J Nanomedicine. 2020 Jul 9;15:4859-4876. doi: 10.2147/IJN.S245170. eCollection 2020.
9
Cardiovascular disease events within 5 years after a diagnosis of breast cancer.乳腺癌诊断后 5 年内的心血管疾病事件。
BMC Cancer. 2020 Apr 21;20(1):337. doi: 10.1186/s12885-020-06838-w.